The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy
Open accessAbstract
BACKGROUND: The leading cause of death among patients with hereditary retinoblastoma is second malignancy. Despite its high rate of efficacy, radiotherapy (RT) is often avoided due to fear of inducing a secondary tumor. Proton RT allows for significant sparing of nontarget tissue. The current study compared the risk of second malignancy in patients with retinoblastoma who were treated with photon and proton RT. METHODS: A retrospective review was performed of patients with retinoblastoma who were treated with proton RT at the Massachusetts General Hospital or photon RT at Boston Children's Hospital between 1986 and 2011. RESULTS: A total of 86 patients were identified, 55 of whom received proton RT and 31 of whom received photon RT. Patients were followed for a median of 6.9 years (range, 1.0 years‐24.4 years) in the proton cohort and 13.1 years (range, 1.4 years‐23.9 years) in the photon cohort. The 10‐year cumulative incidence of RT‐induced or in‐field second malignancies was significantly different between radiation modalities (proton vs photon: 0% vs 14%; P = .015). The 10‐year cumulative incidence of all second malignancies was also different, although with borderline significance (5% vs 14%; P = .120). CONCLUSIONS: Retinoblastoma is highly responsive to radiation. The central objection to the use of RT, the risk of second malignancy, is based on studies of patients treated with antiquated, relatively nonconformal techniques. The current study is, to the authors' knowledge, the first to present a series of patients treated with the most conformal of the currently available external‐beam RT modalities. Although longer follow‐up is necessary, the preliminary data from the current study suggest that proton RT significantly lowers the risk of RT‐induced malignancy. Cancer 2014;120:126–133. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
Cited by
Proton therapy – Present and future
Mohan, R., & Grosshans, D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.006 · Cited by 608
Radiation induced secondary malignancies: a review article
Dracham, C. B., Shankar, A., & Madan, R. (2018) · Radiation Oncology Journal · doi:10.3857/roj.2018.00290 · Cited by 349
Nuclear physics in particle therapy: a review
Durante, M., & Paganetti, H. (2016) · Reports on Progress in Physics · doi:10.1088/0034-4885/79/9/096702 · Cited by 345
Metadata
- Authors
- Sethi, R. V., Shih, H. A., Yeap, B. Y., Mouw, K. W., Petersen, R., Kim, D. Y., Munzenrider, J. E., Grabowski, E., Rodriguez‐Galindo, C., Yock, T. I., Tarbell, N. J., Marcus, K. J., Mukai, S., & MacDonald, S. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-10-02
- Volume
- 120
- Issue
- 1
- Pages
- 126-133
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1496390158
- Cited by
- 174
- References
- 1
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. https://app.cochat.ai/papers/10.1002/cncr.28387
- The paper
- Sethi, R. V., Shih, H. A., Yeap, B. Y., Mouw, K. W., Petersen, R., Kim, D. Y., Munzenrider, J. E., Grabowski, E., Rodriguez‐Galindo, C., Yock, T. I., Tarbell, N. J., Marcus, K. J., Mukai, S., & MacDonald, S. M. (2014). Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. https://doi.org/10.1002/cncr.28387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.